HC Wainwright & Co. Reiterates Buy on Genmab, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Genmab (NASDAQ:GMAB) and maintained a $50 price target, as stated by analyst Raghuram Selvaraju.
August 06, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Genmab and maintained a $50 price target, indicating continued confidence in the company's stock performance.
The reiteration of a Buy rating and maintenance of a $50 price target by a reputable analyst firm like HC Wainwright & Co. is a strong positive signal for investors. It suggests confidence in Genmab's future performance and could lead to increased investor interest and a potential short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100